To assess the long-term efficacy of the triple combination along with a maintenance dose of anti-PD-1 on established liver metastases, we repeated our experiments and injected 5,000 freshly dissociated (unlabeled) T12 tumor cells into the PV. The gene discussed is PDCD1; the disease is neoplasm.